ABOUT US
We are a Danish start-up aiming to transform the diagnosis of genetic disorders for better disease management.
gMendel® approach
Genotyping
We have developed a proprietary method for high-throughput and cost-effective genotyping. By calculating fractions of reads, our diagnostic tool can identify gene mutations and chromosomal aberrations from a normal karyotype and hence recognize genetic disorders.
AI
We harness the full power of analytics and Artificial Intelligence throughout the complete sequencing process. By using machine learning algorithms, our proprietary technology translates real-time data into accurate and meaningful results.
Diagnosis & Treatment
Our transformative approach bridges the gap between new generation genomic tools and their clinical implementation, providing a shorter path to accurate diagnosis and potential treatment.
9 years horizon
Phase 0: Proof of concept
Phase 1: Intelligent diagnosis – gMendel®Test
The gMendel®Test is fully developed. Data validation has been performed in a strongly controlled environment, meeting specific quality criteria of medical protocols.
The gMendel®Test aims to address the diagnostic needs of 350 million families and 6 million births per year, paving the way “from diagnosis to treatment”.
We plan to commercialize a diagnostic tool of 32 genetic disorders, 6 universal prenatal chromosomal aberrations and 26 postnatal, comprising of the most prevalent genetic disorders with treatment in each country.
Our commercialization strategy includes direct sales in Denmark in 2022, followed by the rest of Scandinavia, the Netherlands, Spain, Greece, North Macedonia, Italy, and Switzerland in 2023 and from 2024 onwards, Germany, France, the UK, the USA, Canada, Brazil, Israel, Egypt, Turkey, UAE and Saudi Arabia.
Commercial partnerships will be carried out as gMendel® expands worldwide.
In parallel, we plan to commercialize a full genome sequencing diagnostic tool, leveraging on the full potential of the Phivea™ Platform.
Phase 2: Improving lives of people with genetic disorders and their caregivers – gMendel®Care
Our vision goes beyond technological advancement. With our gMendel®Care initiative, we aim to empower families and their children through social care and equal opportunities, and contribute to building resilient healthcare and welfare systems.
We aim to do this by including the gMendel®Test in national healthcare protocols for prenatal and postnatal diagnosis, creating synergies with pharmaceutical companies to stimulate research and development in orphan drugs, and facilitating collaboration and constructive dialogue with national health policy bodies and platforms.
Phase 3: Intelligent treatment – gMendel®Hope
In the future, we hope to combine the gMendel® method with direct methods in protein crystallography.
Our vision is to shape successful treatment protocols on allogeneic bone marrow transplants, by identifying compatible matches to Major Histocompatibility Complex proteins, more accurately and economically.
Meet the team
Chris
Kyriakidis
PhD, MSc, MBA
Co-founder
Kristijan
Jankoski
MSc
Senior Data Scientist
Thomasz
Puk *
MSc, MBA
Head of Q&R
Dariusz
Nabiałczyk *
MSc Software Architect
Head of Q&R
Zoran
Velkoski
MSc, MBA
Co-founder
David
Galevski
MSc
Data Scientist
Jarosław
Kowalczyk *
MSc
Quality Assurance Manager
Agnieszka
Tymoszyk *
BSc
QA Engineer
Aleksandar
Nikov
BSc
Head of AI
Anne
Schack
MSc
Genomics Researcher
Dimitris
Kyriakidis
MSc
Advocacy Groups
Witold
Lukaszewski *
MSc
Business Analyst
Gjorgji
Madjarov *
PhD, MSc
AI Advisor
Lukasz
Krych *
PhD, MSc
Genomics Advisor
Rafal
Kalka *
MSc
Senior Project Manager
Maria
Andrielou *
MSc, MA
Head of Marketing & Communication
Lukasz: Associate Professor at the University of Copenhagen
Tomasz, Jarosław, Rafal, Dariusz, Agnieszka, Witold: Members of the Star.Global Team
Andrielou: Head of Marketing & Corporate Communication at Plankton First S.A.
Social responsibility
gMendel contributes to the communities where we live. We are committed to our employees, diversity, equity, inclusion, and environmental sustainability.
We have partnered with Besesaka Foundation, a non-profit organization in Bukom, Ghana, aiming to improve education through the power of boxing. Established in 2019, Besesaka aims to establish a Boxucation academy, where boxing is as important as education, by the end of 2023. Until then, Besesaka provides educational scholarships to boys and girls, who love boxing and are great at it, have excellent academic level and demonstrate a great character. Its vision is to develop a new Bukom where all children attend school and graduate, resulting in the elimination of teenage pregnancy and child labor.
Through Besesaka and Boxucation, we contribute to developing better leaders and creating equal opportunities for children, one step at a time.